Abstract:Lung cancer is the most common malignant tumor in the world. The Whole-proteome microarray showed that ubiquitin ligase chromatin assembly factor 1 subunit B (CHAF1B) expression in A549/DDP cells is higher than in A549 cells. Our study explored the molecular mechanism of CHAF1B affecting cisplatin resistance in lung adenocarcinoma (LUAD). Proteome microarray quantify the differentially expressed proteins between LUAD cell line A549 and its cisplatin-resistant strain A549/DDP. Quantitative real-time quantitative polymerase chain reaction (qRT-PCR) and Western blot (WB) confirmed the CHAF1B expression. Public databases analyzed the prognosis of LUAD patients with varied LUAD expression followed by the substrates prediction of CHAF1B. Public databases showed that nuclear receptor corepressor 2 (NCOR2) may be substrates of CHAF1B. WB detected that CHAF1B expression affected the expression of NCOR2. Cell and animal experiments and clinical data detected function and integrating mechanism of CHAF1B compounds. Proteome chips results indicated that CHAF1B, PPP1R13L, and CDC20 was higher than A549 in A549/DDP. Public databases showed that high expression of CHAF1B, PPP1R13L, and CDC20 was negatively correlated with prognosis in LUAD patients. PCR and WB results indicated higher CHAF1B expression in A549/DDP cells than that in A549 cells. NCOR2 and PPP5C were confirmed to be substrates of CHAF1B. CHAF1B knockdown significantly increased the sensitivity of cisplatin in A549/DDP cells and the upregulated NCOR2 expression. CHAF1B and NCOR2 are interacting proteins and the position of interaction between CHAF1B and NCOR2 was mainly in the nucleus. CHAF1B promotes ubiquitination degradation of NCOR2. Cells and animal experiments showed that under the action of cisplatin, after knockdown of CHAF1B and NCOR2 in A549/DDP group compared with CHAF1B knockdown alone, the cell proliferation and migratory ability increased and apoptotic rate decreased, and the growth rate and size of transplanted tumor increased significantly. Immunohistochemistry suggested that Ki-67 increased, while apoptosis-related indicators caspase-3 decreased significantly. Clinical data showed that patients with high expression of CHAF1B are more susceptible to cisplatin resistance. Ubiquitin ligase CAHF1B can induce cisplatin resistance in LUAD by promoting the ubiquitination degradation of NCOR2.

CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Targeting Cul3-scaffold E3 ligase complex <i>via</i> KLHL substrate adaptors for cancer therapy

Systematic Identification of CDC34 That Functions to Stabilize EGFR and Promote Lung Carcinogenesis

The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/Β-Catenin Signaling Pathway

Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells

Skp2-Ubiquitinated MLKL Degradation Confers Cisplatin-Resistant in NSCLC Cells

Genome-wide identification of CDC34 that stabilizes EGFR and promotes lung carcinogenesis

Ubiquitin ligase CHAF1B induces cisplatin resistance in lung adenocarcinoma by promoting NCOR2 degradation

CRL2-KLHDC3 E3 ubiquitin ligase complex suppresses ferroptosis through promoting p14 ARF degradation

Akt kinase LANCL2 functions as a key driver in EGFR -mutant lung adenocarcinoma tumorigenesis

CRL2-KLHDC3 E3 ubiquitin ligase complex suppresses ferroptosis through promoting p14ARF degradation

CDKL3 Promotes Non-small Cell Lung Cancer by Suppressing Autophagy Via Activation of PI3K/Akt/mTOR Pathway.

CRKL is a Critical Target of Hh-GLI2 Pathway in Lung Adenocarcinoma.

Overexpression of ELF3 Facilitates Cell Growth and Metastasis Through PI3K/Akt and ERK Signaling Pathways in Non-Small Cell Lung Cancer

Regulatory Role of KEAP1 and NRF2 in PPARγ Expression and Chemoresistance in Human Non-Small-cell Lung Carcinoma Cells.

Cullin3–KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression

KLHL38 Involvement in Non-Small Cell Lung Cancer Progression Via Activation of the Akt Signaling Pathway.

ARHGEF3 regulates the stability of ACLY to promote the proliferation of lung cancer